The European Commission approved Fruzaqla (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib.
A new partnership between the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and ARcare aims to improve colorectal cancer screening rates in seven rural Arkansas counties where late-stage diagnoses and cancer disparities are on the rise.
